Welcome to PharmAthene
PharmAthene, Inc. (NYSE Amex: PIP), formed in March 2001 is pursuing its mission to become the premier company worldwide specializing in the development and rapid commercialization of best-in-class medical countermeasures for the multi-billion dollar biodefense industry. By following a strategy of acquiring leading compounds and technologies focused only on high priority medical countermeasures solutions identified by the United States and other governments as urgent to procure, PharmAthene has built a solid product pipeline and a strong reputation within the industry. Up to more than $550 million in United States government contract and funding commitments have been awarded to support the Company’s current product development programs.
- SparVax™ - recombinant protective antigen (rPA) anthrax vaccine
- Valortim® - fully human monoclonal antibody antitoxin – treatment of anthrax infection
- Recombinant BChE bioscavenger – prevention and treatment of nerve agent poisoning
- rPA anthrax vaccine - third generation rPA anthrax vaccine
PharmAthene’s core strengths include:
- Unique focus in an industry with committed government funding and high barriers to entry
- Impressive track record with over half a billion dollars in contracts, funding and awards
- Experienced management team with extensive development, commercialization, government affairs and government contracting expertise
A Business to Address the Threat of Chemical and Biological Weapons
The threat of chemical and biological warfare has not been adequately addressed by the established pharmaceutical industry. In recognition of this urgent requirement, the U.S. government has dedicated unprecedented resources to accelerate the research, development and procurement of effective medical countermeasures to combat biological, chemical, nuclear and radiological threats.
Project BioShield, signed into law in 2004, authorizes $5.6 billion in secure funding over ten years for the advanced development and purchase of priority medical countermeasures. In addition, significant annual appropriations are provided through the Biomedical Advanced Research and Development Authority (BARDA), which was established to promote research and development of novel biomedical countermeasures by ensuring adequate advanced development funding for promising technologies in advance of procurement.
In response to this unique market opportunity, PharmAthene has focused on establishing an impressive portfolio of best-in-class medical countermeasures specifically targeting the highest priority biodefense requirements of the U.S. government. To date, the Company has been successful in securing up to more than $550 million in non-dilutive grant and contract funding to support the development of its portfolio products. PharmAthene believes its products are uniquely positioned to capture a significant share of this high value market.
In assembling its portfolio, PharmAthene has adhered to a strategy emphasizing strict selection criteria geared towards ensuring the strongest probability of U.S. government procurement, and the rapid commercialization of its portfolio products. These selection criteria include:
- Demonstration of technical proof of concept in man or robust efficacy in relevant animal models
- Advantages over existing competitive products or technologies
- Demonstrated interest and intent by the U.S. government in procurement
- Clearly defined development and regulatory strategy
PharmAthene has been successful in obtaining non-dilutive funding to finance the development of its products. To date, the Company has been awarded government contracts and grants totaling up to more than $550 million in potential revenues, provided certain milestones are achieved and all options are exercised by the government. The Company continues to demonstrate a strong track record of performance with the U.S. government, and has successfully achieved all performance milestones related to its ongoing government contracts.
PharmAthene became a public company in August 2007 raising approximately $60 million in capital, which was used to acquire relevant products to expand its biodefense portfolio. Prior to going public, PharmAthene had successfully raised approximately $65 million in venture capital and private equity financing from prominent life sciences investors, including, HealthCare Ventures, MPM Capital, Ontario Teacher’s Pension Plan and Fairway Capital. Since becoming a publicly traded company, PharmAthene has raised approximately $65 million in a series of equity and convertible debt offerings.
For additional information about PharmAthene or the Company’s products, or to learn more about the U.S. government’s commitment to biodefense; and / or the U.S. government’s initiatives related to medical countermeasures development and procurement , please visit our website at www.PharmAthene.com, or contact Investor Relations at 410-269-2610.